1stOncology™: Cancer Intelligence Service – Page 14348 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Deciphera Pharmaceuticals, Inc. to Present at the 30th Annual Piper Jaffray Healthcare Conference

On November 20, 2018 Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, reported that Michael D. Taylor, Ph.D., President and Chief Executive Officer, will present at the 30th Annual Piper Jaffray Healthcare Conference on Tuesday, November 27, 2018 at 2:30 PM ET at the Lotte New York Palace Hotel (Press release, Deciphera Pharmaceuticals, NOV 20, 2018, View Source [SID1234531505]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

A live webcast of the event will be available on the "Events and Presentations" page in the "Investors" section of the Company’s website at View Source A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.

Curis to Present at the 60th Annual Meeting of the American Society of Hematology

On November 20, 2018 Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, reported three upcoming poster presentations at the 60th annual meeting of the American Society of Hematology (ASH) (Free ASH Whitepaper) (Press release, Curis, NOV 20, 2018, View Source [SID1234531504]). Curis’s poster presentations will be available for viewing on Monday, December 3 (Session III) from 10 a.m. to 8 p.m. PT with presentations from 6 p.m. to 8 p.m. PT in Hall GH at the San Diego Convention Center.

Curis will present three posters at the ASH (Free ASH Whitepaper) conference providing key information supporting development of fimepinostat in patients with DLBCL, including patients with MYC-alterations, and CA-4948, Curis’s IRAK4 inhibitor, for patients with lymphomas. A pooled analysis of R/R DLBCL patients treated with fimepinostat demonstrates adequate safety and anti-tumor activity supporting the biologic rationale for continued development of fimepinostat in this patient population. Additionally, Curis will present preclinical data and biological rationale that support CA-4948 development in patients with tumors sensitive to the IRAK4 signaling pathway as well as data supporting the potential for IRAK4-based combination regimens to overcome drug tolerance in patients with Non-Hodgkin Lymphoma.

Details of these presentations are as follows:

Curis Presentations at American Society of Hematology (ASH) (Free ASH Whitepaper) 60th Annual Meeting

Viewing Date/Time:

Monday, Dec. 3, 10:00 AM – 8:00 PM PT

Presentation Date/Time:

Monday, Dec. 3, 6:00 PM – 8:00 PM PT

Location:

Hall GH, San Diego Convention Center

Abstract Number:

4168

Presentation Title:

Preclinical Activity of IRAK4 Kinase Inhibitor CA-4948 Alone or in Combination with Targeted Therapies and Preliminary Phase 1 Clinical Results in Non-Hodgkin Lymphoma

Abstract Number:

4184

Presentation Title:

A Pooled Analysis of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients Treated with the Dual PI3K and HDAC Inhibitor Fimepinostat (CUDC-907), Including Patients with MYC-Altered Disease

Abstract Number:

2649

Presentation Title:

Drug Combinations Co-Targeting Myeloid Cell Leukemia-1 (Mcl-1) Protein Can Overcome Microenvironmentally-Induced Multi-Drug Tolerance in Non-Hodgkin Lymphomas

Data from Phase III MAIA Study of Daratumumab Accepted for Presentation at Annual Meeting of American Society of Hematology

On November 20, 2018 Genmab A/S (Nasdaq Copenhagen: GEN) reported that data from the Phase III MAIA study of daratumumab in front line multiple myeloma, which was submitted by our collaboration partner Janssen Biotech, Inc., was accepted as a late-breaking abstract for oral presentation at the 60th Annual Meeting of the American Society of Hematology (ASH) (Free ASH Whitepaper) (Press release, Genmab, NOV 20, 2018, View Source [SID1234531503]). The abstract is now published online on the ASH (Free ASH Whitepaper) website:

LBA-2: Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA) (View Source)

The data will be presented as part of the Late-Breaking Abstracts Session on December 4, 2018 at 7:30 AM PST (4:30 PM CET).

"We are extremely pleased that this new data from the important MAIA study has been chosen for presentation at the prestigious ASH (Free ASH Whitepaper) annual meeting, as it will provide ASH (Free ASH Whitepaper) attendees the opportunity to learn more about the transformative role of daratumumab in the treatment of newly diagnosed patients with multiple myeloma," said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab

Immune Design to Present at Piper Jaffray 30th Annual Healthcare Conference

On November 20, 2018 Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on next-generation therapies in oncology, reported that management will present at the Piper Jaffray 30th Annual Healthcare Conference on Tuesday, November 27, 2018 at 2:30 p.m. Eastern in New York (Press release, Immune Design, NOV 20, 2018, View Source [SID1234531502]).

A live webcast of the presentation will be available online from the investor relations page of the company’s corporate website at View Source After the live webcast, an archive of the presentation will be available on the company website for 30 days.

Aeglea BioTherapeutics to Present at Evercore ISI HealthconX Conference

On November 20, 2018 Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, reported that it will participate in a fireside chat at the Evercore ISI HealthconX Conference in Boston, MA on Tuesday, November 27 (Press release, Aeglea BioTherapeutics, NOV 20, 2018, http://ir.aegleabio.com/news-releases/news-release-details/aeglea-biotherapeutics-present-evercore-isi-healthconx [SID1234531501]).

Presentation Details
Date: Tuesday, November 27, 2018
Time: 2:45 p.m. ET
Location: The Boston Harbor Hotel, Boston, MA
Room: South Atlantic Room (2nd floor)
Webcast: View Source

To access the live and archived audio webcast of the fireside chat, visit the Presentations & Events section of the Aeglea BioTherapeutics investor relations website. Please connect to the website at least 15 minutes prior to the presentation to allow for any software download that may be necessary. Replays of the webcast will be available for 30 days thereafter.